Axol Bioscience appoints Liam Taylor as CEO to drive growth
A new chief executive officer has been appointed to drive growth at Axol Bioscience.
Liam Taylor takes over from founder Dr Yichen Shi in leading the Chesterford Research Park-based biotechnology company, which specialises in providing human cell products.
Axol Bioscience, which also has a US office in Massachusetts, uses stem cell technology to manufacture cell-based assay systems for the drug discovery industry.
In particular, it reprogrammes cells using induced pluripotent stem cell (iPSC) technology and differentiates them into different cell types to supply to researchers.
It also supplies primary cells, cell lines, media and reagents and disease models.
Liam has experience of running commercial, operations, finance and innovation teams in the diagnostic, pharma and life science sector in the UK and US.
Most recently, he was the chief financial officer and then managing director/CEO of BBI Solutions, based in Cardiff, which provides materials and test platforms for the in-vitro diagnostics market.
While there, he helped the company grow its annual revenue from £23million to £52million through organic growth and strategic acquisitions that broadened the company’s offer.
Liam said: “The progress achieved at Axol Bioscience in developing high quality and consistent iPSCs has been impressive, and I am excited to be joining at an exciting point in the company’s development where we will be working to scale up operations to support the rapidly growing biotech and pharmaceutical markets, to support increases in efficiency within drug screening and discovery.”
Prior to working at BBI Solutions, he worked as operations director at tax specialist Nair & Co in Bristol and spent more than five years as a senior manager in the business services division of accountancy and wealth management firm WalterTurnbull in Australia, where he studied accountancy at Australian Catholic University.
Dr Jonathan Milner, chairman of Axol Bioscience, said: “The board is delighted to appoint Liam as Axol’s new CEO. His wealth of experience and comprehensive knowledge of the pharma and life science sector will be invaluable in unlocking the full potential of the company.”